DUBLIN--(BUSINESS WIRE)--The "Pain Management Drugs Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
The pain management drugs market was valued at US$101.189 billion in 2018 and is anticipated to grow at a CAGR of 5.61% to reach a market size of US$140.371 billion by 2024.
The growing geriatric population suffering from pain related to joints and chronic diseases are driving the growth of the global pain management market in the forecast period. Other factors include the prevalence of chronic diseases, rising healthcare expenditures, an increase in the number of accidents and increasing surgical procedures. However, the availability of substitutes such as pain relief devices is hampering the growth of the global pain management drugs market in the forecast period.
Geographically, North America is expected to hold a significant market share owing to the highest health expenditure of the United States in addition to effective disease management owing to the prevalence of chronic diseases in this region.
This report is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by drug type, by indication, and by geography.
The pain management drugs market has been segmented based on drug type, indication, and geography. Based on drug type, the market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, acetaminophen, antidepressants, and anticonvulsant drugs. On the basis of indication, the market has been segmented into cancer, rheumatoid arthritis, chronic back pain, post-operative pain, and others.
Regional analysis has been provided with detailed analysis and forecast for the period 2018 to 2024. The global market has been broken down into North America, South America, Europe, Middle East and Africa (MEA), and the Asia Pacific regions. The report also analyzes 15 major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.
Major players in the pain management drugs market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the pain management drugs market.
Key Topics Covered
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE
5.1. Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.5. Anticonvulsant drugs
6. PAIN MANAGEMENT DRUGS MARKET BY INDICATION
6.2. Rheumatoid Arthritis
6.3. Chronic Back Pain
6.4. Post-Operative Pain
7. PAIN MANAGEMENT DRUGS MARKET BY GEOGRAPHY
7.1. North America
7.2. South America
7.3.2. United Kingdom
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.5. Asia Pacific
7.5.4. South Korea
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Strategies of Key Players
8.3. Recent Investments and Deals
9. COMPANY PROFILES
9.1. Novartis Pharmaceuticals Corporation
9.2. Eli Lilly and Company
9.3. Amgen Inc.
9.4. GlaxoSmithKline plc
9.5. AbbVie Inc.
9.6. Merck & Co., Inc.
9.8. F. Hoffmann-La Roche Ltd.
9.9. Pfizer Inc.
9.10. Purdue Pharma L.P.
For more information about this report visit https://www.researchandmarkets.com/r/yq0q5w